Brief: Neurosense Receives FDA Clearance Of IND For Its ALS Phase 2B Study

Neurosense Therapeutics

15/11/2022 14:15

Nov 15 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE RECEIVES FDA CLEARANCE OF IND FOR ITS ALS PHASE
2B
STUDY
    * NEUROSENSE THERAPEUTICS- PARADIGM CURRENTLY ENROLLING
PATIENTS
IN ISRAEL, EXPECTS TO OPEN CLINICAL SITES FOR PATIENT
RECRUITMENT IN EU IN COMING WEEKS
    * NEUROSENSE THERAPEUTICS LTD - EXPECTS TO ENROLL AND DOSE
FIRST
U.S. PATIENTS IN NEXT FEW WEEKS AT LEADING ALS CENTERS ON BOTH
EAST AND WEST COAST

Source text for Eikon:  ID:nPn1H1LYQa 
Further company coverage:  NRSN.O